Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$11.70
+1.5%
$11.99
$6.55
$13.54
$1.54B1.251.65 million shs398,143 shs
Harrow, Inc. stock logo
HROW
Harrow
$38.61
-2.8%
$40.00
$20.85
$59.23
$1.42B0.27524,430 shs686,088 shs
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$1.75
+0.9%
$1.31
$0.37
$1.83
$400.77M1.771.85 million shs442,673 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$37.21
+0.3%
$35.24
$16.16
$41.57
$1.50B0.83275,667 shs25,684 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
-1.54%+1.14%-6.26%+29.12%+69.06%
Harrow, Inc. stock logo
HROW
Harrow
-5.16%-17.84%-0.08%+26.68%-22.08%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
0.00%+2.37%+39.52%+69.61%+99.17%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-1.36%-9.04%-5.88%+19.17%+68.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$11.70
+1.5%
$11.99
$6.55
$13.54
$1.54B1.251.65 million shs398,143 shs
Harrow, Inc. stock logo
HROW
Harrow
$38.61
-2.8%
$40.00
$20.85
$59.23
$1.42B0.27524,430 shs686,088 shs
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$1.75
+0.9%
$1.31
$0.37
$1.83
$400.77M1.771.85 million shs442,673 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$37.21
+0.3%
$35.24
$16.16
$41.57
$1.50B0.83275,667 shs25,684 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
-1.54%+1.14%-6.26%+29.12%+69.06%
Harrow, Inc. stock logo
HROW
Harrow
-5.16%-17.84%-0.08%+26.68%-22.08%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
0.00%+2.37%+39.52%+69.61%+99.17%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-1.36%-9.04%-5.88%+19.17%+68.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
2.67
Moderate Buy$13.0011.10% Upside
Harrow, Inc. stock logo
HROW
Harrow
2.67
Moderate Buy$68.5077.42% Upside
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
3.00
Buy$4.25143.55% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.13
Hold$28.40-23.67% Downside

Current Analyst Ratings Breakdown

Latest LCTX, HROW, PAHC, and AUPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/8/2025
Harrow, Inc. stock logo
HROW
Harrow
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/1/2025
Harrow, Inc. stock logo
HROW
Harrow
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$70.00 ➝ $74.00
9/29/2025
Harrow, Inc. stock logo
HROW
Harrow
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$42.00 ➝ $70.00
9/29/2025
Harrow, Inc. stock logo
HROW
Harrow
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$64.00
9/29/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
9/27/2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
Harrow, Inc. stock logo
HROW
Harrow
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
9/24/2025
Harrow, Inc. stock logo
HROW
Harrow
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$63.00
9/23/2025
Harrow, Inc. stock logo
HROW
Harrow
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$65.00 ➝ $70.00
(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$235.13M6.55$0.31 per share37.97$2.68 per share4.37
Harrow, Inc. stock logo
HROW
Harrow
$199.61M7.16$0.13 per share306.38$1.95 per share19.80
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$9.50M41.95N/AN/A$0.35 per share4.99
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.16$3.23 per share11.51$7.05 per share5.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$5.75M$0.4327.2220.89N/A23.31%20.06%13.81%11/6/2025 (Estimated)
Harrow, Inc. stock logo
HROW
Harrow
-$17.48M-$0.25N/A96.53N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-$18.61M-$0.12N/AN/AN/A-374.84%-20.00%-12.93%11/13/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$1.1831.4017.721.143.73%32.14%6.89%11/5/2025 (Estimated)

Latest LCTX, HROW, PAHC, and AUPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.17N/AN/AN/A$67.70 millionN/A
11/5/2025Q1 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.58N/AN/AN/A$345.44 millionN/A
8/27/2025Q4 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.57+$0.05$0.42$362.24 million$378.70 million
8/11/2025Q2 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.01$0.24+$0.23$0.13$64.23 million$63.74 million
7/31/2025Q2 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.17$0.16-$0.01$0.16$64.27 million$70.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.29%N/A40.68%N/A

Latest LCTX, HROW, PAHC, and AUPH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.26%9/3/20259/3/20259/24/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.18
5.23
4.63
Harrow, Inc. stock logo
HROW
Harrow
0.78
0.62
0.58
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/A
4.08
4.08
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.46
2.76
1.25

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
62.47%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%

Insider Ownership

CompanyInsider Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
12.20%
Harrow, Inc. stock logo
HROW
Harrow
15.16%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
26.80%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300131.63 million115.57 millionOptionable
Harrow, Inc. stock logo
HROW
Harrow
18037.00 million31.39 millionOptionable
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
60228.36 million167.16 millionNot Optionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.53 million20.21 millionOptionable

Recent News About These Companies

New Strong Buy Stocks for October 7th
Best Income Stocks to Buy for October 7th
New Strong Buy Stocks for September 30th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$11.70 +0.17 (+1.48%)
As of 11:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Harrow stock logo

Harrow NASDAQ:HROW

$38.61 -1.13 (-2.84%)
As of 11:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Lineage Cell Therapeutics stock logo

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.74 +0.02 (+0.87%)
As of 11:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$37.20 +0.10 (+0.26%)
As of 11:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.